ACE-031

ACE-031 is an experimental drug designed to increase muscle mass by blocking myostatin — the protein that naturally limits how big your muscles can grow. **How it works:** Your body produces myostatin to prevent muscles from growing too large. ACE-031 acts as a "decoy receptor" that intercepts myostatin before it can reach muscle tissue, essentially removing the brakes on muscle growth. **What the research shows:** • Developed initially for muscular dystrophy patients to combat muscle wasting • Clinical trials showed significant increases in lean muscle mass • Also increased bone mineral density in studies • Development was halted due to safety concerns (minor nosebleeds and gum bleeding) **The science behind it:** ACE-031 is a fusion protein combining part of the activin receptor (ActRIIB) with an antibody fragment. This allows it to circulate in the bloodstream and bind to myostatin and related proteins (like activin A and GDF-11) that suppress muscle growth. **Important to know:** Clinical development was discontinued by Acceleron Pharma in 2013 after Phase 2 trials due to safety signals. The compound remains investigational and is not approved for any use. --- **Sources:** Attie KM, et al. (2013) Neuromuscular Disorders. DOI:10.1016/j.nmd.2013.02.015 | Campbell C, et al. (2017) Muscle & Nerve. DOI:10.1002/mus.25268

Clinical development was halted after Phase 2 largely because of bleeding-related adverse events (epistaxis, telangiectasias); there are no long-term data on functional outcomes in DMD or other muscle-wasting conditions, and no approved indication.

ACE-031 is a recombinant fusion protein of the extracellular domain of human activin receptor type IIB fused to an IgG1 Fc region; it sequesters myostatin, activin A and GDF-11, blocking catabolic TGF-beta-family signaling in muscle. It was administered by subcutaneous injection in trials; beyond trial reports, no clinical pharmacokinetic data are published.